TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
EMPOWER YOURSELF WITH KNOWLEDGE
Join the EHE Foundation for a special Science Saturday on Rare Disease Day, February 28, 2026, 11:00 am – 12:30 pm ET. This virtual event is designed for anyone affected by EHE who wants an up-to-date view of the EHE research landscape. This free, interactive presentation will highlight Foundation-led research, global scientific advances, and the […]
For the global EHE community, 2025 brought challenges, resilience, and momentum. Grounded in connection and a shared commitment to progress in EHE, we look back with emotion, appreciation, and gratitude, and in 2026, we look forward with determination and hope.
Scientists know that most EHE tumors are caused by specific genetic changes called gene fusions. In most people with EHE, two genes, WWTR1 and CAMTA1, are abnormally fused. In a smaller number of cases, a different fusion involving YAP1 and TFE3 is present. In a recent review published in Critical Reviews in Oncology/Hematology, the authors […]
A recent study published in the European Journal of Cancer represents the largest collection of data from people with EHE in Canada. Researchers found that EHE can behave very differently from person to person—about one-third of patients were diagnosed by chance and did not need immediate treatment, while others had more aggressive disease. About half […]
In a recent issue of AME Case Reports, a team led by Dr. Clifford Atuiri describes a case of pulmonary epithelioid hemangioendothelioma (EHE) and places it within the broader understanding of the disease. The authors note that EHE in the lungs can be difficult to diagnose because symptoms and imaging often resemble more common lung […]
A recent study published in Cancer Control describes a treatment approach for hepatic (liver) EHE called subsegmental bland embolization, which blocks blood flow to individual tumors. In three patients with multiple liver tumors, most treated tumors shrank significantly, and the disease was initially controlled in all patients. The procedure was well tolerated, with no serious […]
Drs. Claudia Giani, Anna Maria Frezza, Silvia Stacchiotti, and colleagues from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and Royal Marsden Hospital, London, UK, presented results from POEM: a prospective observational study on Epithelioid Haemangioendothelioma at ESMO Congress 2025. The data presented included 57 consecutive molecularly confirmed EHE patients who entered the study, […]
You met Jason Hanna, PhD, at the 2025 EHE Global Patient Conference, where he highlighted work his lab is undertaking in EHE. We are thrilled to share a recent publication in Molecular Oncology from the Hanna Lab at Purdue University, highlighting their findings from a study focused on the YAP1-TFE3 subtype of EHE. The YAP1-TFE3 […]
We are thrilled to share a new publication, “EHE cell cultures are a platform for mechanistic and therapeutic investigation,” made possible by a partnership between the University of Iowa and the EHE Foundation. Under the leadership of Dr. Munir Tanas, Nicholas Scalora, PhD, and colleagues in the Tanas Lab sought to develop long-term EHE cell […]